Discovery and Translation of Cancer Immunology: A Special Issue

Collection

1. 1. Cancer Biology

   MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity

   Renumathy Dhanasekaran et al.

   MYC and Twist1 drive metastasis by a novel non-cell-autonomous transcriptional mechanism of eliciting a cytokinome that mediates the crosstalk between cancer cells and macrophages, and its therapeutic blockade inhibits metastasis.
2. 1. Cancer Biology
   2. Immunology and Inflammation

   Inflammation-induced IgE promotes epithelial hyperplasia and tumour growth

   Mark David Hayes et al.

   Natural IgE supports epithelial cell growth and differentiation in healthy skin, but during chronic tissue inflammation, IgE drives tumour outgrowth of epithelial cells harbouring oncogenic mutations.
3. 1. Cancer Biology

   T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity

   Marta Canel et al.

   Cancer cell expression of the T-cell co-stimulatory molecule CD80, or treatment with agonistic antibodies targeting the T-cell co-stimulatory receptors OX-40 or 4-1BB, enhances the anti-tumor activity of FAK inhibition.
4. 1. Cancer Biology
   2. Immunology and Inflammation

   Preclinical murine tumor models: a structural and functional perspective

   Marion V Guerin et al.

   Dissecting structural, cellular and molecular differences between transplanted and spontaneous mouse tumor models, highlighting their relevance for predicting the efficacy of anti-cancer treatments in patients.
5. 1. Cancer Biology

   Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies

   Ana Rita Pombo Antunes et al.

   The heterogeneity of immune cell types in glioblastoma tumors depends on the tumor's genetic make-up and treatment status and is an incompletely mined source of novel therapeutic targets.
6. 1. Immunology and Inflammation

   Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy

   Alok Kumar et al.

   Downregulation of mitochondrial activity by immunosuppressive tumor-derived soluble factors leads to systemic unresponsiveness to the PD-1 blockade therapy.
7. 1. Human Biology and Medicine
   2. Immunology and Inflammation

   SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint

   Emma Hajaj et al.

   SLAMF6 is an inhibitory checkpoint of T cells, the lack of which leads to better tumor control, suggesting a new immunotherapy target.
8. 1. Cancer Biology

   GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab

   Daiki Kato et al.

   The safety and strong antitumor effects of GPC1-specific CAR-T cells against GPC1-expressing solid tumors were demonstrated by using both syngeneic and xenogeneic mouse models.
9. 1. Immunology and Inflammation

   Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma

   Kenji Murata et al.

   A library of the paired peptide/HLA multimers and artificial APCs allows for construction of a large database of class I-restricted peptides and cognate tumor-reactive TCR genes at an unprecedented scale.
10. 1. Cancer Biology
    2. Immunology and Inflammation

    The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy

    Aaron R Lim et al.

    Diverse components of the tumor microenvironment affect T cell metabolism in ways that are crucial to improving immunotherapy.